Core Viewpoint - Envoy Medical, a hearing health company, is set to participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026, highlighting its commitment to innovation in hearing solutions [1]. Group 1: Company Overview - Envoy Medical (NASDAQ: COCH) specializes in innovative technologies for hearing loss, offering fully implanted devices such as the Esteem® active middle ear implant, available in the U.S. since 2010, and the investigational Acclaim® cochlear implant [2]. Group 2: Event Details - The Small Cap Growth Virtual Investor Conference will take place on February 5, 2026, at 10:00 A.M. ET, featuring a presentation followed by a real-time Q&A session for investors [1]. - A recording of the event will be accessible on Envoy's Investor Relations website for those unable to attend the live session [1].

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- (State or other jurisdiction of incorporation or organization) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

Core Insights - Envoy Medical will host a fireside chat featuring CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim cochlear implant, on December 11, 2025, at 4:30 P.M. ET [1][2] Company Overview - Envoy Medical, listed on NASDAQ as COCH, is a hearing health company focused on innovative technologies for hearing loss, including fully implanted devices like the Esteem active middle ear implant and the investigational Acclaim cochlear implant [3][4] - The Acclaim cochlear implant is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA in 2019 [5] Product Details - The Acclaim cochlear implant utilizes a sensor that leverages the natural anatomy of the ear to capture sound, distinguishing it as a first-of-its-kind hearing device [4] - The Esteem fully implanted active middle ear implant is the only FDA-approved device for adults with moderate to severe sensorineural hearing loss, providing continuous hearing without the need for external components [7]

Core Viewpoint - Envoy Medical, Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The upgrade reflects an improvement in Envoy Medical's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - For the fiscal year ending December 2025, Envoy Medical is expected to earn -$1.20 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 4.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Envoy Medical in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

Core Insights - Envoy Medical has secured a new U.S. patent for an innovative cochlear implant system that features a removable earplug sensor and an implanted battery, reinforcing its leadership in next-generation cochlear implant technology [1][2][3] Company Developments - The newly granted patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," enhances Envoy Medical's intellectual property portfolio and covers systems that include an implantable subsystem with a stimulator and rechargeable energy storage [2][3] - The patent supports the company's long-term innovation strategy and aims to protect future advancements in implanted technologies, not just current devices [3] - Envoy Medical is making positive progress in its pivotal Acclaim® Cochlear Implant clinical trial, which has received Breakthrough Device Designation from the FDA in 2019 [3][4][8] Product Information - The Acclaim Cochlear Implant is designed for individuals with severe to profound sensorineural hearing loss and utilizes a sensor that leverages the natural anatomy of the ear instead of a microphone [7][8] - The Esteem® fully implanted active middle ear implant is another innovative product from Envoy Medical, which has been commercially available in the U.S. since 2010 and allows for continuous hearing without external components [5][9]

Core Insights - Envoy Medical, Inc. reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -29.63% [1] - The company generated revenues of $0.04 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 23.64% [2] - Envoy Medical's shares have declined approximately 50.9% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $0.06 million, and for the current fiscal year, it is -$1.17 on revenues of $0.2 million [7] Market Outlook - The earnings outlook and estimate revisions trend for Envoy Medical were favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The Medical - Instruments industry, to which Envoy Medical belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a positive industry outlook [8]

Financial Performance - For the three months ended September 30, 2025, the company reported a net loss of $6,482, compared to a net loss of $5,960 for the same period in 2024, and for the nine months ended September 30, 2025, the net loss was $17,170, compared to $16,177 in 2024[144]. - The company has an accumulated deficit of $305,659 as of September 30, 2025, up from $284,734 as of December 31, 2024[144]. - Net revenues for the three months ended September 30, 2025, were $42, a decrease of $14 or 25.0% compared to $56 in the same period of 2024[186]. - Net revenues decreased by $17, or 9.3%, for the nine months ended September 30, 2025, compared to the same period in 2024[198]. - Cash used in operating activities was $12,516 for the nine months ended September 30, 2025, primarily funding a net loss of $17,170[214]. - As of September 30, 2025, the company had $3,556 in cash, down from $5,483 at the end of 2024[209]. Clinical Trials and Regulatory Approvals - The FDA granted the Investigational Device Exemption (IDE) for the Acclaim CI in October 2024, allowing the company to begin a pivotal clinical study[140]. - The first stage of the clinical trial included 10 participants, and the FDA approved the expansion to a total of 56 participants on October 3, 2025[141][147]. - The second stage of the clinical trial for the Acclaim CI is currently underway, with the first three patients enrolled by October 31, 2025[148]. - The company anticipates obtaining FDA's decision on the Premarket Approval application in the second half of 2027, assuming no panel review is requested[142]. - The company is targeting FDA approval for the Acclaim CI in the second half of 2027 or first half of 2028[166]. Expenses and Costs - Cost of goods sold increased by $16 to $203 for the three months ended September 30, 2025, primarily due to increased material waste[188]. - Research and development expenses for the three months ended September 30, 2025, were $2,700, a slight decrease of $57 or 2.1% from $2,757 in 2024[186]. - General and administrative expenses rose by $752 or 44.5% to $2,442 for the three months ended September 30, 2025, compared to $1,690 in 2024[186]. - The operating loss for the three months ended September 30, 2025, was $5,708, an increase of $736 or 14.8% from a loss of $4,972 in 2024[186]. - The company expects R&D expenses to continue increasing as it initiates clinical trials for the Acclaim CI product[175]. - R&D expenses for the nine months ended September 30, 2025, increased by $225, with personnel costs up 5.2% and other R&D costs up 107.2%[200]. - Total costs and operating expenses increased by $1,161, or 7.8%, with general and administrative expenses rising by 17.7%[197]. Financing Activities - The company entered into a Securities Purchase Agreement on September 22, 2025, to issue 1,908,402 shares of Common Stock at a price of $1.31 per share[154]. - The September 2025 Offering generated gross proceeds of $2,500, with potential additional proceeds of $7,500 if warrants are fully exercised[156]. - The October 2025 Offering resulted in gross proceeds of $4,000, with potential additional proceeds of $12,000 from warrant exercises[160]. - Net cash provided by financing activities for the nine months ended September 30, 2025 was $10,593, resulting from proceeds from the issuance of Term Loans of $10,000[217]. Market and Economic Conditions - The company received a deficiency notification from Nasdaq regarding non-compliance with the market value listing requirement, with a grace period until February 23, 2026, to regain compliance[149][152]. - Macroeconomic conditions, including global conflicts and inflation, are impacting the company's financial performance and capital raising ability[162]. - The company is exposed to inflation risk, which may adversely affect operating results if selling prices do not increase in line with rising costs[237]. Miscellaneous - The gain from the change in the fair value of the forward purchase agreement warrant liability was $64, compared to a loss of $311 in the prior year[192]. - There were no customers accounting for 10% or more of sales for the three and nine months ended September 30, 2025 and 2024, indicating a diversified customer base[236]. - The company has not had any off-balance sheet arrangements during the periods presented, ensuring transparency in financial reporting[220]. - The estimated cost per unit for the product warranty is $6, with an average battery life of five years, impacting the liability recorded[229]. - The company has not experienced any material differences between accrued costs and actual costs incurred since inception, indicating effective cost estimation practices[227].